A patient with HIV presents with a 3-month history of cough and fever, and Miliary tuberculosis is suspected.… - INI-CET EXAM -2025

INI-CET EXAM -2025

Medical Surgical Nursing

Hard

Appeared in: INI-CET EXAM -2025

Explanation

The standard of care for severe HIV-associated tuberculosis is to initiate anti-tubercular therapy (ATT) immediately to control the active infection.
Antiretroviral therapy (ART) should be started soon after, ideally within 2 weeks of ATT initiation, to improve immune status and reduce mortality.
Rifampicin, a key drug in ATT, is a strong enzyme inducer that significantly lowers the blood levels of the ART drug dolutegravir.
To counteract this interaction and prevent ART failure, the dose of dolutegravir must be increased (typically doubled from 50 mg once daily to 50 mg twice daily) when used with a rifampicin-containing regimen.

Option B: This option incorrectly prioritizes ART over ATT. In active, life-threatening tuberculosis, ATT must be started first to control the bacterial infection. Delaying ATT for 2 weeks would be dangerous for the patient.
Option C: This option is incomplete. While an increased dose of dolutegravir is necessary, this action alone does not address the primary problem, which is the active miliary tuberculosis. The patient requires a full ATT regimen.
Option D: This option incorrectly recommends a standard dose of dolutegravir. Using a standard dose alongside rifampicin-based ATT would lead to sub-therapeutic drug levels, risking virological failure and the development of HIV drug resistance.

Visual 1: Flowchart: Management algorithm for HIV-TB co-infection, showing the decision points for starting ATT and ART, and considerations for drug dosing.
Visual 2: Diagram: Illustration of the metabolic pathway showing how rifampicin induces liver enzymes (CYP3A4, UGT1A1) that accelerate the breakdown of dolutegravir, leading to lower drug levels.

Clinical Relevance

Nursing practice connection: Use the key finding related to Management of HIV and Miliary Tuberculosis Co-infection to guide bedside assessment, documentation, and the next nursing action.
Proper sequencing and dosing in HIV-TB co-infection are critical for patient survival. Incorrect management increases the risk of death, treatment failure, and drug resistance.
Nurses must be vigilant for signs of Immune Reconstitution Inflammatory Syndrome (IRIS), a paradoxical worsening of TB symptoms after starting ART, which is more common with early ART initiation but is a manageable risk.
Patient education is key. Nurses must explain the importance of adherence to both complex regimens and the reason for the increased dolutegravir dose to ensure compliance.

How to Approach the Question

First, identify the two primary conditions: HIV and a severe form of tuberculosis (miliary).
Recall the fundamental principle of managing co-infections: treat the most immediate life-threatening condition first. In this case, it is the active miliary TB.
Consider the interplay between the treatments for both diseases. Think about the timing of initiation (which drug first?) and potential drug-drug interactions.
Evaluate each option against these principles: a) ATT must start first. b) ART should follow shortly (within 2 weeks for severe TB). c) Check for known interactions, specifically between rifampicin (in ATT) and dolutegravir (in ART).
Eliminate options that violate these principles. Option B starts ART first. Option C is incomplete. Option D uses the wrong dose. This leaves Option A as the only one that correctly addresses sequence, timing, and dosage.

Concept Tested & Keywords

Concept Tested: Management of HIV and Miliary Tuberculosis Co-infection
Stem keywords: HIV, Miliary tuberculosis, cough, fever, management
Lead-in keywords: next step
Clinical cues: Patient has HIV, indicating a compromised immune system.
Clinical cues: Miliary tuberculosis is a severe, disseminated form of TB requiring urgent treatment.

Q5dhzugmXzblQt7Ull5unh